¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"National Nosocomial Infections Study report."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • crossover study
    ±³Â÷¿¬±¸
  • cross-sectional study
    ´Ü¸é¿¬±¸
  • case comparison study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case referent study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case study
    Áõ·Ê¿¬±¸, »ç·ÊÁ¶»ç
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸, »ç·Ê´ëÁ¶±º¿¬±¸
  • diachronic study
    ºñµ¿½Ã¿¬±¸
  • double blind study
    ÀÌÁ߸Ͱ˿¬±¸
  • ecological study
    »ýÅ¿¬±¸
  • feasibility study
    °¡´É¼º¿¬±¸
  • follow-up study
    ÃßÀûÁ¶»ç
  • family study
    °¡Á·Á¶»ç
  • longitudinal study
    ÃßÀû¿¬±¸
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • prospective study
    ÀüÇ⿬±¸, °èȹ¿¬±¸, ¾Õ¹æÇ⿬±¸, Àü¸Á¿¬±¸
  • prospective cohort study
    ÀüÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸, ȸ°í¿¬±¸
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • single blinding study
    ´Ü¼ø¸Í°Ë¹ý
  • urodynamic study
    ¿ä¿ªµ¿Çа˻ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • case comparison study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case compeer study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case referent study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case-base study
    ȯÀÚ¸ðÁý´Ü¿¬±¸
  • case-control study
    (¢¡retrospective) ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸
  • cohort study
    (¢¡prospective) °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • cross-sectional study
    ´Ü¸éÁ¶»ç¿¬±¸
  • double-blind study
    ÀÌÁ߸Ͱ˹ý
  • study design
    ¿¬±¸°èȹ
  • family study
    °¡Á·Á¶»ç
  • feasibility study
    °¡´É¼º¿¬±¸
  • first pass study
    ÀÏÂ÷Åë°ú°Ë»ç
  • follow-up study
    ÃßÀûÁ¶»ç
  • infection control study
    °¨¿°°ü¸®Á¶»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • prospective study
    °èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£ °Ë»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • skin infections
    ÇǺΰ¨¿°(Áõ)(¡­Êïæøñø)
  • superficial fungus infections
    Ç¥À缺 Áø±Õ°¨¿°(øúî¤àõòØÐ¶Êïæø).
  • transfusion-transmitted infections
    ¼öÇ÷ÀüÆÄ¼º°¨¿°
  • yearly report
    ¿¬º¸(ËçËÓ).
  • hospital acquired (nosocomial) infection
    ¿ø³»°¨¿°(êÂÒ®Êïæø), º´¿ø°¨¿°.
  • hospital acquired (nosocomial) infection
    ¿ø³»°¨¿°, º´¿ø°¨¿°.
  • hospital infection =nosocomial i.
    ¿ø³»°¨¿°(¡­°¨¿°), º´¿ø°¨¿°.
  • hospital infection =nosocomial i.
    ¿ø³»°¨¿°(¡­Êïæø), º´¿ø°¨¿°.
  • infection, nosocomial
    ¿ø³»°¨¿°, º´¿ø³»°¨¿°
  • nosocomial
    (º´)¿ø³»ÀÇ
  • nosocomial
    º´¿ø³»(ËÓËôËÀ)ÀÇ.
  • nosocomial gangrene
    ¿ø³»±«Àú(êÂÒ®ÎÕîÅ).
  • nosocomial gangrene
    ¿ø³»±«Àú(ËôËÀË´Ëø).
  • nosocomial infection
    ¿ø³»°¨¿°
  • nosocomial infection
    ¿ø³»°¨¿°(ËôËÀ˧Ëç).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NHS Nance-Horan syndrome; National Health Service; National Hospice Study; normal horse serum; normal hu...
EF study Ejection-Fraction study
KAP study Knowledge, Attitude & Practice study
AASK African American Study of Kidney Diseases and Hypertension Pilot Study
NCA National Certification Agency; National Council on Aging; National Council on Alcoholism; neurocircu...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NI Nosocomial infection
NP Nosocomial pneumonia
Study 1 study
Study 2 study
Study A study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • case study
    Áõ·Ê ¿¬±¸
  • coagulation study
    ÀÀ°í °Ë»ç
  • controlled clinical study
    °ü¸®È­ ½ÃÇè, °ü¸®È­ ÀÓ»ó ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ÀÓ»ó ½ÃÇè
  • cross-sectional study
    Ⱦ´Ü ¿¬±¸¹ý, Ⱦ´Ü Á¶»ç¹ý
  • double-blind study
    ÀÌÁß ¸Í°Ë ¿¬±¸
  • electroencephalographic study
    ³úÆÄ °Ë»ç
  • enzyme marker study
    È¿¼Ò Ç¥Áö ¿¬±¸
  • longitudinal study
    ´©³âÀû ¿¬±¸, Á¾Àû ¿¬±¸, Á¾´Ü ¿¬±¸¹ý
  • microbiologic study
    »ý¹°ÇÐÀû °Ë»ç
  • microinjection study
    ¹Ì¼¼ ÁÖ»ç ¿¬±¸
  • mounted study cast
    ºÎÂøµÈ Áø´Ü ¸ðÇü
  • neurophysiological study
    ½Å°æ »ý¸®ÇÐÀû ¿¬±¸
  • phase 1 study
    ÀÓ»ó Á¦1»ó ½ÃÇè
  • prospective study
    ÀüÇâÀû ¿¬±¸, ÃßÀû ¿¬±¸
  • psychophysical study
    Á¤½Å ½ÅüÇÐ ¿¬±¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
national institute for occupational safety and health An institute of the centres for disease control and prevention which is responsible for assuring safe and healthful working conditions and for developing standards of safety and health. Research activities are carried out pertinent to these goals.
(12 Dec 1998)
national institute of mental health A component of the national institutes of health concerned with research, overall planning, promoting, and administering mental health programs and research.
(12 Dec 1998)
National Institutes of Health <organisation> A nonregulatory U.S. Federal agency which has oversight of research activities that the agency funds.
(09 Oct 1997)
national library of medicine An agency of the national institutes of health concerned with overall planning, promoting, and administering programs pertaining to various aspects of documentation and library services in the field of medicine.
(12 Dec 1998)
national practitioner data bank A databank established by the health care quality improvement act of 1986 authorizing the department of health and human services to collect and release information on the professional competence and conduct of physicians, dentists, nurses, and other health care practitioners. The data include adverse actions on physicians' malpractice, licensure, hospital privileges, concealing of pertinent information, and the like.
(12 Dec 1998)
National Science Foundation <organisation> A nonregulatory U.S. Federal agency which has oversight of biotechnology research activities that the agency funds.
(09 Oct 1997)
united states national aeronautics and space administration An independent federal agency established in 1958. It conducts research for the solution of problems of flight within and outside the earth's atmosphere and develops, constructs, tests, and operates aeronautical and space vehicles.
(12 Dec 1998)
los alamos national laboratory <radiobiology> Major DOE research facility, located in Los Alamos, new Mexico, about an hour west of Santa Fe. Former home of a frozen-deuterium-fibre Z-pinch device, which was dismantled. Home to an active theory division, including the Numerical Tokamak Grand Challenge (being performed on the CM-5 massively-parallel supercomputer). Also home to former alternative-concepts experimental devices like Scyllac, FRX-A, FRX-B, FRX-C/LSM, ZT40, and the aborted CPRF which was killed in 1991 when it was almost complete (budget cuts). Currently there are some small in-house experiments, including one on electrostatic confinement as a possible fusion device, and/or a compact neutron source. They also do theory and experimental collaboration with other labs worldwide.
(09 Oct 1997)
analytic study In epidemiology, a study designed to examine associations, commonly putative or hypothesised causal relationships; usually concerned with identifying or measuring the effects of risk factors or with the health effects of specific exposures.
(05 Mar 2000)
blinded study Clinical trials of drugs are often done blinded so that the patient does not know (is blinded as to) whether they are receiving the product being tested or the control/placebo to ensure that the results of a study are not affected by a possible placebo effect (by the power of suggestion).
(12 Dec 1998)
blind study A study in which the experimenter is unaware of which group is subject to which procedure.
(05 Mar 2000)
case-control study <epidemiology> A study in which the risk factors of people with a disease are compared with those without a disease.
It is an epidemiological method that begins by identifying persons with the disease or condition of interest (the cases) and compares their past history of exposure to identified or suspected risk factors with the past history of similar exposures among persons who resemble the cases but do not have the disease or condition of interest (the controls).
The relationship of an attribute to the disease can therefore be examined by comparing affected and non-affected individuals with regard to the frequency or levels of the attribute in each group.
(05 May 2002)
retrospective study <epidemiology> A study in which people are enrolled and then have their history of risks, infections or disease measured.
(05 Dec 1998)
rosenzweig picture-frustration study A projective test depicting cartoon-like characters in frustrating situations. The scoring of the subject's responses indicates the direction of hostility or aggression, that is, whether he blames himself, the other person, or the set of circumstances.
(12 Dec 1998)
cohort study A study using epidemiological methods, such as a clinical trial, in which a cohort with a particular attribute (e.g., smokers, recipients of a drug) is followed prospectively and compared for some outcome (e.g., disease, cure) with another cohort not possessing the attribute.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • field study
    =FIELDWORK
  • home study
    (Åë½Å ±³À°¿¡¼­ÀÇ)ÀÚÅà ÇнÀ;(¹Ì)(¾çºÎ¸ð·Î¼­ÀÇ ÀûºÎ¸¦ ¾Ë¾Æº¸´Â)°¡Á¤Á¶»ç
  • home study
    Åë½Å±³À°
  • nature study
    ÀÚ¿¬°øºÎ(²É »õ ±¤¼® ³¯¾¾µîÀÇ °üÂû,±¹¹ÎÇб³ÀÇ Çаú ''
  • study
    ½ÀÀÛ;½ÃÀÛ;¼­Àç;¿¬±¸½Ç;¾Ö¾¸
  • study
    ÇÏ´Ù;¾Ö¾²´Ù;(¹Ì)¼÷°íÇÏ´Ù
  • study
    ÇÏ´Ù;(´ë»çµîÀ»)¾Ï±âÇÏ´Ù
  • national
    ±¹°¡(¹Î)ÀÇ,(º¹¼ö)µ¿Æ÷
  • Grand National
    (¿µ±¹ Liverpool¿¡¼­ ÇØ¸¶´Ù 3¿ù¿¡ ¿­¸®´Â)´ëÀå¾Ö¹° °æ¸¶
  • Indian National Congress
    Àεµ ±¹¹ÎȸÀÇ(ÆÄ)(1885³â¿¡ °á¼º)
  • National Assistance
    (¿µ)±ØºóÀÚ º¸Á¶±Ý
  • National China
    (´ë¸¸ÀÇ)±¹¹ÎÁ¤ºÎ;ÁßÈ­¹Î±¹(the Republic of China)
  • National Congress
    (ÀεµÀÇ)±¹¹ÎȸÀÇÆÄ
  • National Convenant
    (½ºÄÚ»ç)±¹¹Î¼­¾à(ÁÖ±³Á¦¿¡ ¹Ý´ëÇÑ Àå·Î±³È¸ÆÄÀÇ ¼­¾à)
  • National Convention
    (ÇÁ¶û½º»ç)±¹¹Î°øÈ¸;(¹Ì)(Á¤´çÀÇ)Àü±¹´ëȸ;Àü´ç´ëȸ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á